BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, January 6, 2025
Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards
See today's BioWorld Science
Home
» Shionogi's S-217622 shows in vitro antiviral activity against SARS-CoV-2 Omicron subvariant BA.2.75
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Shionogi's S-217622 shows in vitro antiviral activity against SARS-CoV-2 Omicron subvariant BA.2.75
Aug. 10, 2022
No Comments
Shionogi has reported that S-217622 (ensitrelvir fumaric acid), the company's orally administered antiviral drug for COVID-19, shows high in vitro antiviral activity against the SARS-CoV-2 Omicron subvariant BA.2.75.
BioWorld Science
Infection
